4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Galectin Therapeutics Inc. (GALT) operates in the Biotechnology industry and is headquartered in Norcross, United States with about 9 employees. Its market capitalization is roughly $288 million. In the fiscal year ended 2025-12-31, GALT reported $0M in revenue and ($31M) in net income.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($20M) | ($42M) | ($38M) | ($38M) |
| Net Income | ($31M) | ($47M) | ($41M) | ($39M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($4M) | ($3M) | ($4M) | ($5M) | ($8M) |
| Net Income | ($5M) | ($6M) | ($8M) | ($8M) | ($10M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $20M | $18M | $28M | $21M | — |
| Total Liabilities | $146M | $121M | $88M | $54M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GALT viewer.
About TickerBase · Data methodology & sources